A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies.

Trial Profile

A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Salirasib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Metaplasia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Mar 2009 End date added from ClinicalTrials.gov.
    • 20 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Mar 2009 New source identified and integrated (ClinicalTrials.gov NCT00867230).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top